Veranova Bidco LP v Johnson Matthey [2026] EWHC 1021 (Comm): Warranties, disclosure, and the limits of fraud in SPA litigation

The Commercial Court’s decision in Veranova Bidco Lp v Johnson Matthey Plc and other companies [2026] EWHC 1021 (Comm) provides a detailed and practical examination of some of the issues that can arise in M&A disputes, including:

• when a warranty is false;
• what constitutes “fair disclosure”; and
• what is required to invoke the fraud carve-out in a warranty claim.

While the Claimant succeeded on breach of warranty, the claim ultimately failed because the SPA restricted recovery absent fraud, and fraud could not be established. Proving fraud will be particularly important in M&A deals because (as a matter of public policy and common law principles) it is not possible to exclude liability for fraud. If the buyer can prove that the seller was fraudulent, the effect will be that it can pursue the seller directly, notwithstanding limitations on liability in the transaction documentation. Likewise, in a transaction where there is a buyer-side warranty and indemnity insurance policy, the seller will be at risk if fraud is alleged and proven, and that risk is potentially uncapped. The case is therefore a useful illustration of risk allocation through contractual structuring being upheld in litigation. It also highlights the benefits of a structured and well-managed disclosure process in the context of M&A transactions.

Factual background

The dispute arose from Veranova’s acquisition of Johnson Matthey’s “Health Business” under an SPA signed on 16 December 2021. One of the business’s leading products was buprenorphine hydrochloride (BHCL), with its largest customer being Alvogen Inc (Alvogen).

A key feature of the Alvogen Supply Agreement was a price match clause, which allowed Alvogen to initiate discussions with the Health Business in the event that it received a bona fide competing offer from a third party manufacturer which was at least 8% lower than the price charged under the supply agreement.

In October 2021, Alvogen presented such an offer (“the Olesen Offer”) which was an offer to supply BHCL at around US$8/g, and thereby much lower than the existing US$16/g. The Olesen Offer, if accepted, would entail a near 50% price reduction, with potentially significant and detrimental consequences for the business.

The SPA contained the following standard business warranties (“Business Warranties”):

“Business Warranty 1.4.2: Since the applicable Accounts Date … the Businesses [i.e. the Health Business] have been carried on in the ordinary and usual course consistent with past practice and so as to maintain the Businesses as going concerns, without any … material alteration to the nature, scope or manner of the Businesses.” (The “Ordinary and Usual Business Course Warranty”.) 

Business Warranty 8.1.2: None of the Companies … is currently renegotiating any material term of any Key Contract, which upon conclusion, would have an adverse or detrimental effect on the Businesses.”[1](The “Key Contracts Warranty”.)

Critically, however, the SPA contained limitations on liability and business warranty claims unless they arose from fraud or wilful misconduct.

The Claimant’s case initially proceeded on the basis that fraudulent misrepresentations were made by the General Counsel of the Health Business management team, amongst others, during due diligence calls and in the disclosure letter. Those allegations were withdrawn, and the claim proceeded solely as a breach of warranty claim. 

Corporate lawyers and their clients will be familiar with the fact that parties are generally free to agree how far warranties in a sale agreement may be qualified, typically through a disclosure letter.

The following specific disclosures were made in relation to the Business Warranties:

“Since the applicable Accounts Date, increased competition in the market for the Businesses' buprenorphine products has adversely impacted, and continues to adversely impact, the Businesses' market share in that market and the prices that the Businesses are able to charge their customers for these products. Pricing discussions in relation to this issue are ongoing with Alvogen. The projected financial impact of this issue cannot be quantified as at the date of this letter but the impact of this issue on the financial performance of the Businesses during the relevant periods is reflected in the Q1 Accounts and the September 2021 Accounts.”…”[2](Emphasis added.)

The warranty analysis

Ordinary and Usual Course Warranty

The court rejected the allegation that the business had not been carried on in the ordinary course.[3]

Mrs Justice Dias emphasised that pricing negotiations are “entirely to be expected” in long-term supply relationships[4], particularly in markets characterised by price erosion; and the warranty looks at what has occurred (from the Accounts Date to the date of the SPA), not what may occur in the future.[5] Since renegotiations had not yet concluded by the SPA date, and no operational change had occurred, there was no breach.

Key Contracts Warranty

In contrast, the court found that there had been a breach of the Key Contracts Warranty.

The reasoning is notable. It was agreed that the Alvogen Supply Agreement was a key contract. A successful breach of the Key Contracts Warranty had to show that there were renegotiations as to a material term of a key contract, and that those renegotiations would have an adverse or detrimental effect on the Health Business.

The court was of the view that the invocation of the price match clause initiated a renegotiation process, even if not formally labelled as such.[6] It held that the anticipated price drop was plainly capable of having an adverse or detrimental effect, irrespective of whether or not it could be fully quantified[7]. By the SPA date, it was sufficiently clear that the Health Business would likely have to match (or closely approach) the Olesen pricing to retain Alvogen. Accordingly, the warranty was false as at signing.[8]

Disclosure: What is “Fair”?

The more significant part of the judgment concerns disclosure. There is no common law definition of “fair disclosure”. The courts will examine the drafting in the agreement and apply usual contractual principles to determine the level of disclosure required. The SPA’s definition of “Disclosed” was as follows: “fairly disclosed with sufficient detail to allow a reasonable buyer to make an informed assessment of the nature and scope of the matter concerned”[9]. This is a very commonly used formulation. 

As part of the analysis of this, the court considered the relevance of extraneous statements e.g. what was said during due diligence calls, or in prior correspondence. Mrs Justice Dias held that the question of disclosure is confined to the contractual agreement: which in this case was the Disclosure Letter. It is open to the parties to agree the form and extent of any disclosure that will be deemed to be adequate against warranties, and in this case the business warranties were subject to what was disclosed in the Data Room.[S&B1] 

The Disclosure Letter referred to increased competition; and ongoing pricing discussions with Alvogen. However, it did not disclose certain other information (such as the Olesen Offer triggering the price match clause, or the fact that Alvogen had asked the Health Business to match the price in the Olesen Offer amongst other things).

The court drew a distinction between generalised disclosure (market pressure, negotiations), and specific, transaction-critical information (a concrete third-party offer halving prices).

Mrs Justice Dias held that fair disclosure required disclosure of the existence of a verified bona fide competing offer at around US$8/g; and the commercial reality that the Health Business would need to match the offer around that price in order to retain Alvogen’s business.[10] The failure to disclose those matters meant the Key Contracts Warranty was not adequately qualified, and a breach was established.

This is a particularly useful articulation of the “nature and scope” limb in the definition of “Disclosed”. Even if a disclosure is sufficient for a buyer to make an informed assessment about the “nature of the matter concerned”, the buyer must also be able to assess the scope. [11] In other words, not just what is happening, but how serious it is.

Mrs Justice Dias stated that: “In my judgment the appropriate test should be whether the brief particulars provided enable a purchaser to say “I want to see more about X” where X is the matter which needs to be disclosed. If the purchaser is not even alerted to the possibility that there might even be an “X”, then the deeming provisions cannot apply.” The relevant circumstance for disclosure was the objective fact that in order to retain Alvogen’s business, the Health Business would need to match the offer or at least come close. 

Fraud: The real battleground

There was no dispute that the Defendants had given the warranties in question, and since Mrs Justice Dias had found that the Key Contracts Warranty was false, and had not been adequately qualified by disclosure, the question then addressed by the court was whether this arose from the fraud or wilful misconduct of one or more of the Johnson Matthey executives (“JM Executives”). 

The court adopted a conventional approach, outlining the law, that fraud requires that the relevant individual:

• knew the warranties breached were false; or
• gave the warranties without belief in their truth; or
• was reckless as to whether they were true or false.[12] 

Mrs Justice Dias stressed that fraud must exist in one individual. It is necessary to find a dishonest state of mind in an individual whose state of mind is either attributable to the defendant by way of the principles of agency or is treated as being that of the defendant by virtue of corporate attribution. But it cannot be constructed by aggregating partial knowledge across multiple people.[13] The idea of “composite fraud” is not recognised (e.g. if an officer of a company makes a statement and  honestly believes it to be true,  yet others in the company know the statement is false, there will not be a fraud).[14] This is a clear reaffirmation of Armstrong v Strain principles in a modern M&A context.[15]

Application to the JM Executives

The Claimant focused on four senior executives. However, the court made a number of critical factual findings. Although some executives knew of the Olesen Offer, they did not have sufficient awareness of the warranties and disclosure position.[16] Others involved in the transaction did not know about the Olesen Offer at all.[17] All of the executives relied on a standard and apparently robust disclosure process involving internal and external lawyers.[18]

The judge was particularly clear that reliance on a proper disclosure process is not “recklessness” and at most, failures amounted to potential negligence, not dishonesty. 

The claim therefore failed and none of the JM Executives were found to be guilty of fraud, wilful misconduct or conscious dishonesty. 

Practical takeaways

• Disclosure must be specific, not generic. General references to “pricing pressure” will not suffice where there is a known, concrete commercial trigger.

• “Fair disclosure” depends on how that term is defined in the agreement but typically requires both nature and scope. A buyer must be able to understand how serious the issue is, not just that it exists.

• Fraud carve-outs are extremely difficult to invoke. Even where a warranty is false, and disclosure is inadequate, a claim will fail unless actual dishonesty can be shown.

• There is no aggregation of knowledge. You must identify an individual who both knew the relevant facts; and appreciated the falsity of the warranty.

• A structured disclosure process involving management sign-off and legal review can be persuasive evidence against any claims of fraud. Equally, a willingness on the part of executives or management to err on the side of caution in the disclosure process is helpful. 

• This case involved a major global company, and the senior executives were not involved in the detail of disclosing against the warranties. In businesses with smaller management teams where the executives running the business are the same individuals as are involved in the disclosure process, it might arguably be easier to show that one or more individuals had the “conscious dishonesty” necessary to support a fraud claim. This highlights the need for seller’s advisers to ensure that the management team is properly advised on disclosure that will meet the definition of “fair disclosure” in the agreement. 

• As always in the context of any disputes, contemporaneous documentation to corroborate witness oral testimony is very powerful when assessing evidence. 

• Where (as here) warranty and indemnity backed structures restrict claims to fraud, courts will enforce that bargain strictly.

Conclusion

This decision is a useful example of a successful breach case that nonetheless fails overall due to contractual risk allocation. For sellers, it highlights the importance of targeted disclosure that meets the definition of “fair disclosure” in the agreement.
For buyers, it is a sharp reminder that if you agree to a fraud-only route, you are accepting a very high bar.